Advertisement

European Journal of Clinical Pharmacology

, Volume 28, Issue 1, pp 41–43 | Cite as

Atenolol inhibits the elimination of disopyramide

  • J. Bonde
  • S. Bødtker
  • H. R. Angelo
  • T. L. Svendsen
  • J. P. Kampmann
Originals

Summary

The effect of atenolol on the total elimination of disopyramide and its main dealkylated metabolite was studied in 6 patients and 3 volunteers. During administration of 50 mg atenolol b.i.d. the clearance of disopyramide decreased significantly (p<0.02) from 1.90±0.71 (X±SD) to 1.59±0.68 ml/kg/min, while its half-life, concentration of the metabolite, and the volume of distribution remained unchanged. The reduction in the clearance of disopyramide by atenolol might contribute to the alleged pharmacodynamic interaction between disopyramide and β-blocking drugs.

Key words

disopyramide atenolol pharmacokinetics drug interaction ischaemic heart disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Singh BN, Vaughan Williams M (1972) A fourth class of antidysrhytmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular potentials and on other features of cardiac function. Cardiovasc Res 6: 109–119PubMedCrossRefGoogle Scholar
  2. 2.
    Gelipter D, Hazell M (1980) Interaction between disopyramide and practolol. Br Med J 1: 52Google Scholar
  3. 3.
    Cumming AD, Robertson C (1979) Interaction between disopyramide and practolol. Br Med J 4: 1264CrossRefGoogle Scholar
  4. 4.
    Lima JJ (1979) Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite. Clin Chem 25: 405–408PubMedGoogle Scholar
  5. 5.
    Karim A, Nissen C, Azarnoff DL (1982) Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 10: 465–494PubMedCrossRefGoogle Scholar
  6. 6.
    Deano DA, Wu D, Mautner RK, Sherman RH, Ehsani AE, Rosen KM (1977) The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 71: 597–606PubMedCrossRefGoogle Scholar
  7. 7.
    Chiang WT, von Bahr C, Calissendorff B, Dahlqvist R, Magnusson A, Schenck-Gustavsson K, Vuorosalo D, Sjöqvist F (1982) Plasma concentration and effect of disopyramide and its mono-dealkylated metabolite administered to healthy subjects. Br J Clin Pharmacol 14: 590PGoogle Scholar
  8. 8.
    Burk M, Peters U (1983) Disopyramide kinetics in renal impairment: Determinants of interindividual variability. Clin Pharmacol Ther 34: 331–340PubMedGoogle Scholar
  9. 9.
    Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J (1978) Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 13: 81–89PubMedCrossRefGoogle Scholar
  10. 10.
    Perrild H, Mølholm Hansen J, Skovsted L, Korsgaard Christensen L (1983) Different effects of propranolol, alprenolol, sotalol and metoprolol on serum T3 and rT3 in hyperthyroidism. Clin Endocrinol 18: 139–142CrossRefGoogle Scholar
  11. 11.
    Cathcart-Rake WF, Coker JE, Atkins FL, Huffman DF, Hassanein KM, Shen DD, Azarnoff DL (1980) The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. Circulation 61: 938–945PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • J. Bonde
    • 1
  • S. Bødtker
    • 1
  • H. R. Angelo
    • 1
  • T. L. Svendsen
    • 1
  • J. P. Kampmann
    • 1
  1. 1.Departments of Internal Medicine P and Clinical ChemistryBispebjerg HospitalCopenhagenDenmark

Personalised recommendations